Inventor
DESNOYERS LUC ROLAND
US21 patents
Patents
21 patentsUS9120853B2Sep 1, 2015
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC52 citations97
US10745481B2Aug 18, 2020
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC22 citations94
US9889211B2Feb 13, 2018
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC29 citations94
US10533053B2Jan 14, 2020
Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor
CYTOMX THERAPEUTICS INC12 citations93
US10233244B2Mar 19, 2019
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC26 citations93
US10179817B2Jan 15, 2019
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC36 citations93
US9540440B2Jan 10, 2017
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC31 citations93
US9545442B2Jan 17, 2017
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC19 citations92
US9517276B2Dec 13, 2016
Compositions and methods for conjugating activatable antibodies
CYTOMX THERAPEUTICS INC24 citations92
US9737623B2Aug 22, 2017
Antibodies that bind activatable antibodies and methods of use thereof
CYTOMX THERAPEUTICS INC19 citations91
US11753466B2Sep 12, 2023
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC7 citations85
US11267896B2Mar 8, 2022
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC10 citations85
US10709799B2Jul 14, 2020
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC10 citations84
US11180562B2Nov 23, 2021
Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies
CYTOMX THERAPEUTICS INC5 citations83
US10568977B2Feb 25, 2020
Antibodies that bind activatable antibodies and methods of use thereof
CYTOMX THERAPEUTICS INC8 citations82
US11220544B2Jan 11, 2022
Anti-CD166 antibodies and uses thereof
CYTOMX THERAPEUTICS INC8 citations78
US11890354B2Feb 6, 2024
Activatable antibodies that bind epidermal growth factor receptor and methods thereof
CYTOMX THERAPEUTICS INC2 citations73
US12139543B2Nov 12, 2024
Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
CYTOMX THERAPEUTICS INC1 citations72
US12502439B2Dec 23, 2025
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11992528B2May 28, 2024
Compositions and methods for conjugating activatable antibodies
CYTOMX THERAPEUTICS INC0 citations60
US12498367B2Dec 16, 2025
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
CYTOMX THERAPEUTICS INC0 citations43